These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32451345)

  • 1. Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Feb; 80(2):e26. PubMed ID: 32451345
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e78. PubMed ID: 32759253
    [No Abstract]   [Full Text] [Related]  

  • 3. Are patients with systemic lupus erythematosus at increased risk for COVID-19?
    Favalli EG; Gerosa M; Murgo A; Caporali R
    Ann Rheum Dis; 2021 Feb; 80(2):e25. PubMed ID: 32451344
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli
    Romão VC; Cruz-Machado AR; Fonseca JE
    Ann Rheum Dis; 2021 May; 80(5):e76. PubMed ID: 32561609
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev
    Spinelli FR; Ceccarelli F; Di Franco M; Conti F
    Ann Rheum Dis; 2021 Feb; 80(2):e20. PubMed ID: 32345618
    [No Abstract]   [Full Text] [Related]  

  • 6. SLE patients are not immune to covid-19: importance of sending the right message across.
    Goyal M
    Ann Rheum Dis; 2021 Feb; 80(2):e23. PubMed ID: 32327426
    [No Abstract]   [Full Text] [Related]  

  • 7. Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie
    Gamboa-Alonso CM; Figueroa-Parra G; Galarza-Delgado DA
    Ann Rheum Dis; 2021 Jan; 80(1):e7. PubMed ID: 32571868
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e70. PubMed ID: 32737109
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
    Sbidian E; Penso L; Herlemont P; Botton J; Baricault B; Semenzato L; Drouin J; Weill A; Dray-Spira R; Zureik M
    Ann Rheum Dis; 2023 May; 82(5):e117. PubMed ID: 32859610
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e72. PubMed ID: 32669304
    [No Abstract]   [Full Text] [Related]  

  • 11. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
    Peschken CA
    J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
    Moiseev S; Avdeev S; Brovko M; Novikov P; Fomin V
    Ann Rheum Dis; 2021 Feb; 80(2):e19. PubMed ID: 32317315
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis.
    Spinelli FR; Ceccarelli F; Di Franco M; Conti F
    Ann Rheum Dis; 2021 Jan; 80(1):e9. PubMed ID: 32366521
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India.
    Goyal M; Patil P; Pathak H; Santhanam S; Goel A; Sharma V; Pandey A; Gupta N; Jain R; Akerkar S; Das P; Dudam R; Mendiratta N; Pandey BD; Cb M; Singh BK; Kumar S; Nolkha N; Jain S; Jain S; Sharma A; Misra DP
    Ann Rheum Dis; 2021 May; 80(5):e71. PubMed ID: 32669305
    [No Abstract]   [Full Text] [Related]  

  • 15. No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit.
    Romão VC; Cruz-Machado AR; Fonseca JE
    Ann Rheum Dis; 2021 Feb; 80(2):e22. PubMed ID: 32404340
    [No Abstract]   [Full Text] [Related]  

  • 16. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
    Monti S; Montecucco C
    Ann Rheum Dis; 2020 Jun; 79(6):e62. PubMed ID: 32327429
    [No Abstract]   [Full Text] [Related]  

  • 17. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
    Parperis K
    Ann Rheum Dis; 2021 Jan; 80(1):e8. PubMed ID: 32321722
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to: 'Implications of SARS-CoV-2 infection for patients with rheumatic disease' by Lin
    Mathian A; Amoura Z
    Ann Rheum Dis; 2022 Aug; 81(8):e153. PubMed ID: 32895236
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of SARS-CoV-2 infection for patients with rheumatic disease.
    Lin C; Wang Z; Li J; Xia X; Liu Y; Wang Q
    Ann Rheum Dis; 2022 Aug; 81(8):e152. PubMed ID: 32792333
    [No Abstract]   [Full Text] [Related]  

  • 20. Does hydroxychloroquine prevent the transmission of COVID-19?
    Heldwein FL; Calado A
    Ann Rheum Dis; 2020 Jun; 79(6):e60. PubMed ID: 32295788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.